


# *Nutritional Management in Esophageal Cancer*

*Kurt Boeykens*

*Nutrition Nurse Specialist*



## *Are these patients nutritionally at risk?*

- If surgery: 'Major surgery'
- Preoperative treatment
  - Chemotherapy and radiation
- Adaptation period postoperative
- Often inhibited food passage
  - Dysphagia, odynophagia


## Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit

Aoife M. Ryan\*, Suzanne P. Rowley, Laura A. Healy, Philomena M. Flood, Narayanasamy Ravi, John V. Reynolds

Clinical Nutrition (2006) 25, 386–393

**Table 1** Nutritional status at diagnosis per morphology in 205 oesophagectomy cases.


Median BMI (kg/m <sup>2</sup> ) at diagnosis	25.5 (16.0–42.13)
Median weight loss	5.3 (0–40.3%)
Clinically severe weight loss*	34%
Clinically significant weight loss**	8%
Non-significant weight loss	58%
> 10% weight loss	29%
Actively losing weight at diagnosis	74%
<i>Subjective global assessment</i>	
SGA severe	6%
SGA mild-moderately malnourished	25%
SGA well nourished	47%
Unavailable	22%
<i>Nutritional risk index</i>	
Not malnourished	47% (96)
Mild malnutrition	16% (33)
Moderate malnutrition	29% (59)
Severe malnutrition	4% (8)



# *Elective surgery*

## *Esophagectomy*

# ASPEN: Nutrition Care Process



# Preoperative nutrition support

## Translating Evidence-Based Practice Guidelines Into a Summary of Recommendations for the Nutrition Management of Upper Gastrointestinal Cancers


Yangyang Lu and Sharon Carey

*Nutr Clin Pract* 2014 29: 518 originally published online 6 May 2014

DOI: 10.1177/0884533614532501

**Table 4.** Key Recommendations for Clinical Practice.

- Patients with upper gastrointestinal (UGI) cancer should undergo nutrition screening and, where found to be at risk, assessed by a dietitian using a validated tool on admission to the hospital.
- Preoperative nutrition support is required only when malnutrition is identified or intake is likely to be greatly reduced.
- Oral or enteral nutrition is recommended to commence within 24 hours of UGI surgery. Parenteral nutrition should be used only when the enteral route is not accessible or requirements are not able to be met by the enteral route alone.
- Nutrition support has a very limited role to play in the patient with UGI cancer who is palliative.
- The patient with UGI cancer should have access to a multidisciplinary health team.



**Mini Nutritional Assessment (MNA)**

1. Appetite

2. Mobility

3. Anorexia

4. Weight loss

5. Subjective weakness

6. Anorexia

7. Subjective weakness

8. Anorexia

9. Subjective weakness

10. Anorexia

11. Subjective weakness

12. Anorexia

13. Subjective weakness

14. Anorexia

15. Subjective weakness

16. Anorexia

17. Subjective weakness

18. Anorexia

19. Subjective weakness

20. Anorexia

21. Subjective weakness

22. Anorexia

23. Subjective weakness

24. Anorexia

25. Subjective weakness

26. Anorexia

27. Subjective weakness

28. Anorexia

29. Subjective weakness

30. Anorexia

31. Subjective weakness

32. Anorexia

33. Subjective weakness

34. Anorexia

35. Subjective weakness

36. Anorexia

37. Subjective weakness

38. Anorexia

39. Subjective weakness

40. Anorexia

41. Subjective weakness

42. Anorexia

43. Subjective weakness

44. Anorexia

45. Subjective weakness

46. Anorexia

47. Subjective weakness

48. Anorexia

49. Subjective weakness

50. Anorexia

51. Subjective weakness

52. Anorexia

53. Subjective weakness

54. Anorexia

55. Subjective weakness

56. Anorexia

57. Subjective weakness

58. Anorexia

59. Subjective weakness

60. Anorexia

61. Subjective weakness

62. Anorexia

63. Subjective weakness

64. Anorexia

65. Subjective weakness

66. Anorexia

67. Subjective weakness

68. Anorexia

69. Subjective weakness

70. Anorexia

71. Subjective weakness

72. Anorexia

73. Subjective weakness

74. Anorexia

75. Subjective weakness

76. Anorexia

77. Subjective weakness

78. Anorexia

79. Subjective weakness

80. Anorexia

81. Subjective weakness

82. Anorexia

83. Subjective weakness

84. Anorexia

85. Subjective weakness

86. Anorexia

87. Subjective weakness

88. Anorexia

89. Subjective weakness

90. Anorexia

91. Subjective weakness

92. Anorexia

93. Subjective weakness

94. Anorexia

95. Subjective weakness

96. Anorexia

97. Subjective weakness

98. Anorexia

99. Subjective weakness

100. Anorexia



**SNAO**  
Short Nutritional Assessment Questionnaire

Did you lose weight unintentionally?  
More than 6 kg in the last 6 months  
More than 3 kg in the last month

Did you experience a decreased appetite over the last month?

Did you use supplemental drinks or tube feeding over the last month?

no intervention  
moderately malnourished; nutritional intervention  
severely malnourished; nutritional intervention and treatment dietitian


Nutritional Risk Screening (NRS) (ESPEN guideline)			
Impaired nutritional status		Severity of disease (= requested stress-metabolism)	
Mild	Weight loss >5% in 3 months Or Food intake <50-75% of normal requirement in preceding week	Mild	Hip fracture (9) Chronic patients, in particular with acute complications: orthosis (11), COPD (12) Chronic: Anorexia, diabetes, malignant oncology
Score 1		Score 1	
Moderate	Weight loss >5% in 2 months Or BMI 18.5 - 20.9 + impaired general condition Or Food intake 25-50% of normal requirement in preceding week	Moderate	Major abdominal surgery (13-15) Stroke (16) Severe pneumonia, malignant oncology
Score 2		Score 2	
Severe	Weight loss >5% in 1 month (= >15% in 3 months) (17) Or BMI <18.5 + impaired general condition (17) Or Food intake 0-25% of normal requirement in preceding week	Severe	Head injury (18, 19) Bone marrow transplantation (20) Intensive care patients: CAPACHE-10
Score 3		Score 3	
Score:		Score:	= TOTAL SCORE




# *Nutritional assessment*

- Weight loss
  - Recent weight loss and UBW
- Handgrip dynamometry
- GI problems
- Swallowing difficulties
- Diet history/intake
- **Laboratory parameters**
- **BMI (Age-Gender BMI percentiles)**

## Men's Body Mass Index vs Age



## Women's Body Mass Index vs Age



## bmi calculator and body weight comparison

$$\text{BMI} = \text{kg/m}^2$$

This **bmi calculator** calculates **body mass index** from your Weight and Height and also shows how your weight compares to others of the same height

Weight	<input type="text"/>	pounds ▼	<small>can convert lbs to kg</small>
Height	<input type="text"/>	inches ▼	or 5' ▼ 6' ▼
Calculate	results:	<b>Body Mass Index:</b>	<input type="text"/> kg/m <sup>2</sup>

"Male" is the initial setting on this page.

Age:	<input type="text"/>	years (	Adult ▼	)
Gender:	Male ▼	re-calculate		

Women may prefer to bookmark the

Body Description:	<input type="text"/>
UPDATED -> According to: WHO - CDC ▼	
Your Weight is at <input type="text"/> compared to others of same Height and Age	
If you are at <b>50<sup>th</sup> percentile</b> , you are close to the <b>average</b> weight. At 90 <sup>th</sup> percentile, your weight is greater than 90% of others. At 20 <sup>th</sup> percentile, then 80% of others weigh more than you. ( Compared to American's weights )	

Study Type:	Observational	Estimated Enrollment:	650
Study Design:	Observational Model: Cohort	Study Start Date:	July 2013
	Time Perspective: Retrospective	Estimated Study Completion Date:	June 2014
		Estimated Primary Completion Date:	October 2013

Official Title: Age and Gender Corrected Body Mass Index: When Preoperative Weight Loss and Underweight Are Becoming Clinically Significant in Esophagectomy for Cancer.

#### Groups/Cohorts

AG-BMI < 10 pct

Patients who's peroperative BMI is less than the 10th centile

AG-BMI  $\geq$  10th pct

Patients who's peroperative BMI equals or is greater than the 10th centile

#### Detailed Description:

Age-Gender specific BMI percentiles are more accurate compared to the current BMI classes in predicting Overall Survival (OS) after esophagectomy for cancer. Furthermore we believe in a more devastating impact on OS from underweight and not from overweight.

By preoperatively identifying risk patients for poorer OS, especially the non-tumoral deaths, this can be a tool to tailor postoperative nutritional strategies to counter further weight loss and bringing postoperative weight to normal ranges.

## Conclusie AG-BMI

Het 10<sup>de</sup> AG-BMI-percentiel toont een significant **groter aantal patiënten met niet-oncologisch gerelateerde mortaliteit**

- zowel op 1 jaar (13,5% vs. 6,3%;  $p=0,0086$ )
- als 3 jaar (30,2% vs. 15,5%;  $p<0,0001$ )

na slokdarmresectie

H. Van Veer, MD

*Thoraxheelkunde*

*Najaarssymposium VVKVM, 14 december 2013*

# Albumin

## Preoperative albumin and surgical site identify surgical risk for major postoperative complications

KA Kudsk, EA Tolley, RC DeWitt, PG Janu, AP Blackwell, S Yeary and BK King

*JPEN J Parenter Enteral Nutr* 2003 27: 1

*Mortality by site of surgery and preoperative albumin level*


	Albumin category						
	1	2	3	4	5	6	7
ESO	1/1 (100)	—	0/4 (0)	3/11 (27)	1/13 (7.7)	1/25 (4)	1/5 (20)
STOM	2/4 (50)	0/6 (0)	1/16 (6.3)	6/27 (22)	4/33 (12.1)	0/46 (0)	0/8 (0)
PANC	0/1 (0)	2/4 (50)	2/11 (18.2)	3/17 (17.6)	0/32 (0)	0/30 (0)	0/11 (0)
Colon	1/7 (14.3)	3/14 (21.4)	3/19 (16)	4/40 (10)	1/54 (2)	1/68 (1.5)	0/19 (0)
Total	4/13 (31)	5/24 (21)	6/50 (12)	16/95 (17)	6/132 (5)	2/169 (1)	1/43 (2)

Deaths/number per group (percentage of deaths).

Serum albumin categories were defined as follows: 1, 1.75 g/dL; 2, 1.76 to 2.25 g/dL; 3, 2.26 to 2.75 g/dL; 4, 2.76 to 3.25 g/dL; 5, 3.26 to 3.75 g/dL; 6, 3.76 to 4.25 g/dL; 7, >4.25 g/dL.

ESO, esophagus; STOM, stomach; PANC, pancreas.

# Albumin



▲ esophagectomy

**Preoperative albumin and surgical site identify surgical risk for major postoperative complications**


KA Kudsk, EA Tolley, RC DeWitt, PG Janu, AP Blackwell, S Yeary and BK King

*JPEN J Parenter Enteral Nutr* 2003 27: 1

# Sarcopenia

Table 1: Examples of SMI & BMI findings from the analysis of CT images from 1476 patients with solid tumours of the respiratory or gastrointestinal tracts


Subject	SMI (skeletal mass index)	BMI (body mass index)	Comment
<b>B1</b>	29.8 cm <sup>2</sup> /m <sup>2</sup>	40.2 kg/m <sup>2</sup>	Huge variation in BMI with similar SMI
<b>B2</b>	29.8 cm <sup>2</sup> /m <sup>2</sup>	28.1 kg/m <sup>2</sup>	
<b>B3</b>	29.7 cm <sup>2</sup> /m <sup>2</sup>	15.3 kg/m <sup>2</sup>	



# Cancer treatment toxicity

Table 2: Association between sarcopenia incidence of CTT and time to tumour progression (TTP) in metastatic breast cancer patients receiving capecitabine treatment

Parameter	Percentage (%)	Comment
<b>Presence of sarcopenia</b>	Approx 25% of total	Observed in normal weight, overweight & obese patients
<b>Cancer treatment toxicity (CTT)</b>	50% in sarcopenic group 20% in non-sarcopenic group	P=0.03
<b>Time to tumour progression (TTP)</b>	101.4 days in sarcopenic group 173.3 days in non-sarcopenic group	P=0.05



Incidence of dose-limiting toxicity is increased in sarcopenic patients:

Colorectal: 5FU p=0.001  
 Breast: Capecitabine p=0.039  
 Breast: Adjuvant FEC p= 0.03  
 Lung: platinum regimen p=0.000  
 Renal cell: Sorafenib p=0.04

# Preoperative nutrition support

## Translating Evidence-Based Practice Guidelines Into a Summary of Recommendations for the Nutrition Management of Upper Gastrointestinal Cancers

Yangyang Lu and Sharon Carey

*Nutr Clin Pract* 2014 29: 518 originally published online 6 May 2014

DOI: 10.1177/0884533614532501

**Table 4.** Key Recommendations for Clinical Practice.

- 
- Patients with upper gastrointestinal (UGI) cancer should undergo nutrition screening and, where found to be at risk, assessed by a dietitian using a validated tool on admission to the hospital.
  - Preoperative nutrition support is required only when malnutrition is identified or intake is likely to be greatly reduced.
  - Oral or enteral nutrition is recommended to commence within 24 hours of UGI surgery. Parenteral nutrition should be used only when the enteral route is not accessible or requirements are not able to be met by the enteral route alone.
  - Nutrition support has a very limited role to play in the patient with UGI cancer who is palliative.
  - The patient with UGI cancer should have access to a multidisciplinary health team.
-

- Energy dense and protein rich food or beverages
  - Milkshakes, smoothies
- Adequate chewing, slowly eating
- Frequent meals
- Soft/pureed/blenderized/liquid meals
  - Increase the volume for adequate intake!
- Meat substitutes
  - Eggs, boneless fish, tofu, cheese,....

**Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer**




Fig. 1 Logistics of the intensive nutritional support by the dietician. W, week; M, month.

# Immunonutrition

## ESPEN Guidelines on Enteral Nutrition: Surgery including Organ Transplantation ☆

Clinical Nutrition (2006) 25, 224–244



ELSEVIER

ESPEN GUIDELINES

Type of formula	In most patients a standard whole protein formula is appropriate.	C
	Use EN preferably with immuno-modulating substrates (arginine, $\omega$ -3 fatty acids and nucleotides) perioperatively independent of the nutritional risk for those patients	A
	<ul style="list-style-type: none"> <li>• undergoing major neck surgery for cancer (laryngectomy, pharyngectomy)</li> <li>• undergoing major abdominal cancer surgery (oesophagectomy, gastrectomy, and pancreatoduodenectomy)</li> <li>• after severe trauma.</li> </ul>	
	Whenever possible start these formulae 5–7 days before surgery	C
	and continue postoperatively for 5 to 7 days after uncomplicated surgery.	C



© RCS Pro GmbH

# Immunonutrition



**Consensus Recommendations From the U.S. Summit on Immune-Enhancing Enteral Therapy**  
*JPEN J Parenter Enteral Nutr* 2001 25: S61  
DOI: 10.1177/014860710102500213



- A. Patients undergoing elective gastrointestinal (GI) surgery
1. Moderately or severely malnourished patients (albumin < 3.5 g/dL) undergoing major elective upper GI procedures on the esophagus, stomach, pancreas (with or without duodenum), and hepatobiliary tree; the greatest benefit will be achieved in patients who are malnourished preoperatively



© RCS Pro GmbH

# NCP Preop

- Nasogastric feeding tube
- (Surgical/laparoscopic/endoscopic) jejunostomy
- PEG?



*Am J Surg.* 2014 Mar;207(3):361-5; discussion 364-5. doi: 10.1016/j.amjsurg.2013.10.012. Epub 2013 Dec 19.

## **Esophagectomy in patients with prior percutaneous endoscopic gastrostomy tube placement.**

Wright GP<sup>1</sup>, Foster SM<sup>2</sup>, Chung MH<sup>3</sup>.

### **Author information**

### **Abstract**

**BACKGROUND:** The impact of preoperative percutaneous endoscopic gastrostomy (PEG) tube placement in patients undergoing esophagectomy is uncertain.

**METHODS:** A retrospective review was performed in consecutive patients who underwent esophagectomy. Patients were divided into groups based on whether or not they had preoperative PEG placement.


**RESULTS:** One hundred seventeen patients were studied, 102 without (PEG-) and 15 with PEG+ before PEG tube placement. The overall morbidity and mortality rates were 38% and 3%, respectively. The use of a gastric conduit was similar between groups (94% PEG- vs 87% PEG+,  $P = .27$ ), and the presence of a PEG before PEG tube placement was not prohibitive in any case. Anastomotic leak rates were similar between groups (11% PEG- vs 15% PEG+,  $P = .65$ ), and there were no leaks from previous PEG sites.

**CONCLUSION:** It appears that preoperative PEG tube placement has no adverse effect on the performance of esophagectomy and may be considered in highly selected patients with poor nutritional status.



**Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers.**

Ellrichmann M<sup>1</sup>, Sergeev P, Bethge J, Arit A, Topalidis T, Ambrosch P, Wiltfang J, Fritscher-Ravens A.

- 50 patients: oropharyngeal (ENT) and esophageal malignancies
- Need for EN
- 40 pull-through technique/10 direct insertion
- Cytological assessment (brush cytology) at insertion site immediately after placement and after 3-6 months
- With pull technique:
  - 22,5% malignant cells after insertion
  - 9,4 % after 3-6 months only in patients with esophageal cancer
- **Use direct access**




# Esophagectomy



# *NCP postop*

- Danger anastomotic leak
  - NG tube placed at surgery for decompression
    - Protects esophagogastric anastomosis 5-7 days
- Needle catheter jejunostomy or larger bore jejunostomy
  - Also useful after discharge to prevent further weight loss in the adaptation period (nocturnally) and during adjuvant therapy
  - Or when stricture development at the anastomosis site later

# Jejunostomy



# *Type of feeding*

- Enteral feeding (evt. immunonutrition) can start 12 hours after placement
  - Start at 20 ml/h and advance by 10 ml/h every 12 hours until reaching goal
  - Mostly 1 Kcal/ml
- Flush frequently (ever six hours!)
- Avoid high fibre formula and medications (obstruction of the tube)
- Consider semi-elemental tube feeding with small diameters

# Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit

Aoife M. Ryan\*, Suzanne P. Rowley, Laura A. Healy, Philomena M. Flood, Narayanasamy Ravi, John V. Reynolds



**Table 2** Nutrition support post-operatively in 205 oesophagectomy cases.

Days on nutrition support	15 (2–112)
Days on full NS	11 (2–112)
Days on part NS	3 (0–48)
Days fasting	0 (0–10)
Days to first BM	5
Peri-op weight loss (kg)	1.5 (0–25.6)
Peri-op weight loss	2.3% (0–26)
Mean weight on discharge (kg)	71 (39–125.7)
Mean BMI on discharge	24.6 (16.3–40.6)
<i>Weight loss classification</i>	
Non-significant weight loss	65% (133)
Significant weight loss	8% (16)
Severe weight loss	24% (56)
Enteral feeding	189 (92%)
Parenteral feeding	16 (8%)
Intravenous fluids only	0 (0%)

NS = nutrition support; BM = bowel motion.

**Table 3** Biochemical, gastrointestinal and mechanical complications of jejunostomy feeding in 205 cases.

	Incidence
<i>Electrolyte supplementation</i>	
Phosphate	37% (76)
Potassium	32% (66)
Sodium	8% (16)
Magnesium	20% (42)
<i>Gastrointestinal complications</i>	
Constipation	18% (38)
Laxative requirement	26% (54)
Diarrhoea > 3/day	11% (22)
Diarrhoea < 3/day	11% (22)
Nausea	16% (33)
Cramps	6% (13)
Abdominal distension	4% (9)
Vomiting	3% (7)
<i>Mechanical complications</i>	
Tube dislodged	2.4% (5)
Tube occlusion	3% (6)
Tube split	0.5% (1)
Infection at entry site	1.4% (3)
Site oozing	1.4% (3)
Bowel obstruction/volvulus	1.4% (3)

## Jejunostomy tube feeding in patients undergoing esophagectomy

**Canadian Journal of Surgery**

2013;56(6)409-414

**Table 4. Jejunostomy complications**

Patient	Days to oral intake	Days to jejunostomy tube complication	Complication	Treatment
1	12	7	Jejunal ischemia	Localized resection
2	62	8	Bowel obstruction and perforated jejunum	Localized resection
3	NA*	13	Small bowel leak and localized abscess	Repair of jejunum
4	11	10	Jejunal site infection	Tube removed
5	52	49	Jejunal site infection	Tube removed
6	8	6	Jejunal site infection	Antibiotics

NA = not applicable.  
\*Patient died on postoperative day 27 without having resumed oral intake.

# *NCP Postop*

- **Transition to oral intake (if no complications)**
  - Water from D5 (?)
  - Quick progression from clear liquids to soft diet to solid food (= patient specific)
  - Small frequent meals (6-8 per day)
    - Prevents dumping syndrome (abdominal pain, nausea, dizziness, diarrhoea)
  - Later gradually progress to normal diet and 3 meals/d (Patient specific + may take several months)

# *NCP postop*

- **TPN**
  - First week postop (?)
  - Prolonged ileus
  - Intolerance enteral feeding
  - No jejunostomy present

# Postoperative problems



- Swallowing problems
- Reflux
- Dumping syndrome (nausea, diarrhoea, abdominal cramping,...)
- Excess gas
- Rebound hypoglycaemia
- Suboptimal intake-weight loss
- Delayed gastric emptying

[Ann Thorac Surg.](#) 2009 Jun;87(6):1708-13; discussion 1713-4. doi: 10.1016/j.athoracsur.2009.01.075.

**Prevention of delayed gastric emptying after esophagectomy: a single center's experience with botulinum toxin.**

[Martin JT](#)<sup>1</sup>, [Federico JA](#), [McKelvey AA](#), [Kent MS](#), [Fabian T](#).

# *Problem solving*

- Limit fluids during meals
- Avoid alcohol, caffeine (reflux)
- Sit upright 30-60 minutes after eating and two hours before bedtime
  - Bed: upper body 30°
  - Last snack at least two to three hours before going to bed
- Sweets at the end of a meal
- Trial and error




# *Qol afterwards*

- Potentially influenced by some physical (nutritional related) symptoms
  - Dysphagia
  - Loss of taste
  - Further weight loss
  - Early satiety
  - Reflux
  - Blown up feeling
  - Food not going down
  - Chest pain

## Quality of Life After Transhiatal Compared With Extended Transthoracic Resection for Adenocarcinoma of the Esophagus

A.G.E.M. de Boer, J.J.B. van Lanschot, J.W. van Sandick, J.B.F. Hulscher, P.F.M. Stalmeier, J.C.J.M. de Haes, H.W. Tilanus, H. Obertop, and M.A.G. Sprangers



Physical functioning 9 months to one year to baseline

# *Esophageal cancer*

*Surgery not possible*

# NCP

- Screening/assessment
- Dietary counseling
- NST
- Nutrition Care plan
- Stenting
- Gastrostomy-jejunostomy
- TPN

# Conclusions

- Multiple reasons and time points for developing nutrition risk or undernutrition.
- Importance of (preoperative) nutritional screening and assessment
- Develop a individual NCP certainly if at risk or undernourished

# Conclusions

- Use preferable oral/enteral nutrition and if not accessible or requirements not met:  
TPN
- Access to a multidisciplinary team
  - NST
- Patients may need several months to return to their baseline preoperative state.

